15 Jun 2015
Lonza to Expand Viral Therapy Business with Planned Construction of New Facility in Houston, TX
  • Lonza plans to construct a new state-of-the-art 100,000 square foot facility (9,300 square meters) in the Houston, TX (USA) area to meet the increasing demand for viral therapy products
  • The new facility is expected to develop and manufacture both viral gene therapies and virally modified cell therapies
  • The GMP facility design will further showcase Lonza's use of single-use disposable platforms in modular clean-rooms and will include a fully segregated fill/finish suite


Basel, Switzerland, 16 June 2015 – Lonza, a global leader in the field of viral and cell therapy manufacturing, announced today the planned expansion of its industry-leading viral gene therapy business. Lonza plans to construct a new 100,000 square foot facility for viral and immunotherapy development and manufacturing in the Houston, TX (USA) area, complete with a fully segregated fill/finish suite. This new facility will more than double Lonza’s capacity for the production of viral gene and virally modified therapeutics.

The state-of-the-art multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.

"The clinical landscape for targeted gene therapies continues to grow at a steady rate with new advancements in cancer immunotherapies and cardiovascular disease," said Andreas Weiler, Ph.D, Head of Emerging Technologies for Lonza’s Pharma&Biotech segment. "This investment will allow Lonza to be well positioned to meet the demands of this growing market and to remain at the forefront of the viral gene therapy industry. Our viral team has more than 20 years of experience in viral vector gene therapy that, when combined with our newly constructed leading edge facility, will provide a key advantage to our customers and ultimately to their patients.